Dianne Carmichael

Dianne Carmichael

Diane Carmichael


President & CEO
Carmichael Worldwide Inc., Canada

Business Lecturer
DeGroote School of Business

With over 25 years of extensive executive management and start up experience, Dianne has had the opportunity to work in four distinct industries – Consumer Packaged Goods, Technology, Financial Services and Healthcare. She has been involved in multi-national, entrepreneurial and growth companies, rising to President and CEO in two of those industries.

In 2004, Dianne’s father was diagnosed with cancer, affecting her profoundly. This led to a major shift in her career and personal focus. Dianne chose to make a difference in the lives of Canadians stricken with profound illness by advocating and championing for patients, contributing to the highest quality of care in Canada and working to transform the health care system through disruptive innovation.

As the former President of Best Doctors Canada, she is credited with growing a strong consumer movement and market for remote second opinion and healthcare navigation services, resulting in Best Doctors becoming one of the most sought after employee benefits. With Dianne’s leadership, Best Doctors Canada now makes a difference in the lives of over 5 million Canadians and 40 million globally – changing diagnosis 22% of the time and modifying treatment 61% based on tens of thousands of second opinions. In addition to her role as President, Dianne helped drive the global branding and go-to-market effort of the Best Doctors organization, which operates in 30+ countries worldwide.

In 2012, Dianne was appointed Founder & President of UHN Solutions at UHN (Toronto General Hospital, Toronto Western Hospital, Princess Margaret Cancer Centre & Toronto Rehab Hospitals).  Her role at UHN Solutions combined her passion for patient advocacy and empowerment with her belief that unique funding models can be created to help feed Canada’s universal healthcare eco-system – ultimately enhancing the quality of care for all Canadians. She was a member of the Executive Team and International Business Committee Member.

In 2014 Dianne was acting CEO of a digital health technology startup, taking it from ideation to MVP and contracts in the US and Canada within 6 months.

Prior to her leadership roles in the healthcare industry, Dianne created and spearheaded Worldsource Wealth Management (a subsidiary of publicly-traded Guardian Capital Group Ltd.) where she was Chairman and CEO. While overseeing four operations nationally – with three reporting Presidents and 1,200 employees and Advisors – Dianne, grew Worldsource Wealth Management to more than $8 billion in AUA.

Before taking the helm at Worldsource, Dianne was with TD Waterhouse where she was promoted to Vice-President. She built, and later sold, one of the largest individual investment advisory practices, focused exclusively on sophisticated investors.

Earlier in her career, Dianne held progressively more senior sales and marketing management roles at leading consumer packaged goods organizations including Procter & Gamble, Gillette, RJReynolds-Nabisco and in technology organizations such as Memorex-Telex.

Dianne is currently a Board Member at Holland-Bloorview Kid’s Rehabilitation Hospital and The Patient Canada and is Co-Chair of Operation Smile Canada Gala.  Dianne also sits on the Advisory Boards of CAPCH (Canadian Association of People-Centred Health), ARC (academic e-health research collaborative), York University’s Faculty Heath. Dianne is a Business Lecturer at McMaster University’s DeGroote School of Business.

As an international keynote speaker and expert panelist, Dianne has spoken at podiums such as The Economic Club. She writes for the Huffington Post, PolicyMatters, and Health & Lifestyle Magazine. Dianne has been interviewed extensively about healthcare, innovation, leadership and branding in the media and on television, including the Globe and Mail, BNN, SunMedia TV, The Charles Adler Show and CBC.  She has been profiled twice on the cover of Women’s Post Magazine and interviewed for FIND YOUR GREAT WORK, a series highlighting major international leaders who have made significant contributions to society and business.

Dianne is a member of two CEO groups – TEC (The Executive Committee) and IWF (International Women’s Forum), which represents 6,500 female CEOs globally.

Dianne holds a Bachelor of Arts degree from the University of Waterloo.  She also holds a 3-year Business Diploma in Marketing, and various investment industry designations including CIM1, PFP, CSC Honours, CPH, and Officers and Directors.

In 2009, Dianne was recognized as one of the Top 20 Business Women in Canada, she has been nominated for Entrepreneur of the Year and was profiled as one of the Top Women to Watch in 2012. Schulich School of Business profiled her amongst the Top 100 Business Leaders in Canada.  She was recognized one of Canada’s Top Women Transforming Health Care 2015.

Dianne’s dream is to drive disruptive innovation that will positively impact healthcare, leading to sustainable, consumer-centred transformation.

Guided by this dream, Dianne founded Carmichael Worldwide Inc. in 2011 to provide executive leadership, innovation, commercialization while bringing digital health and consumer health & wellness solutions. The focus is on helping dynamic healthcare and wellness organizations whose mandates include enhancing the quality of patient care, enhancing the patient experience or impacting system sustainability through disruptive innovation, technology, delivery systems or unique funding models.

In 2015 Dianne was appointed Managing Director, Health Innovation & Ventures at MaRS Discovery District, North America’s largest Urban Innovation Hub. In this role, she hopes to exponentially impact health care globally by helping to scale Canada’s most innovative health ventures – driving innovation and economic advantage – with those digital technologies poised for global impact.

Return to Board of Directors

Lalit Aggarwal

Lait Aggarwal


President 

Manor Park Holdings, Canada

Lalit Aggarwal is President of Manor Park Holdings.  Previously, Lalit invested for H.I.G. European Capital Partners, Soros Fund Management, and Goldman Sachs.  He is a past fellow of the C.D. Howe Institute and a former Director of Bridgepoint Health.  Lalit holds degrees from the University of Oxford and the University of Pennsylvania and is also a current Director of the Hospital for Sick Children Foundation.

Return to Board of Directors

Peter Lewis

Peter Lewis

Associate Vice-President, Research and Innovation
Global Research Partnerships

Professor Peter Lewis was appointed Associate Vice-President, Research of the University of Toronto in October, 2009. A highly respected and accomplished biochemist, Professor Lewis has been an academic leader, faculty member and researcher at U of T since 1974. Prior to joining the Office of the Vice-President, Research and Innovation, Professor Lewis served as Vice-Dean, Research and International Relations in the Faculty of Medicine for seven years. In that role, he distinguished himself through his leadership of the Faculty’s research enterprise, encompassing 27 departments, more than 4,000 faculty and approximately $600 million in direct research funding annually. He also had direct oversight of several Faculty research centres, such as the Terrence Donnelly Centre for Cellular and Biomolecular Research, the Structural Genomics Consortium and the Banting and Best Diabetes Centre. He served as Chair of the U of T Department of Biochemistry from 1991-2001. Professor Lewis serves on the boards of Bloorview Kids Rehab and the St. Michael’s Hospital Research Institute. His research interests include the structure and function of chromosomes with specific reference to gene regulation. Professor Lewis received his undergraduate education at the University of Calgary and his doctorate at Cornell University.

Return to Board of Directors

Vivek Goel

Vice President, Research and Innovation
University of Toronto, Canada

Professor Vivek Goel is Vice-President, Research and Innovation, and Strategic Initiatives at the University of Toronto and a Professor in the Institute of Health Policy, Management and Evaluation at the Dalla Lana School of Public Health. Professor Goel is a distinguished scholar with an extensive background in teaching, research and university administration. He obtained his medical degree from McGill University and completed post-graduate medical training in Community Medicine at the University of Toronto. Dr. Goel obtained an MSc in Community Health from U of T and an MS in Biostatistics from Harvard University School of Public Health. His research has focused on health services evaluation and the promotion of the use of research evidence in health decision-making.

Professor Goel joined the University of Toronto in 1991 as Assistant Professor in the Department of Preventive Medicine and Biostatistics. He was chair of the Department of Health Administration in the Faculty of Medicine from 1999 until 2001, then served as Vice-Provost, Faculty and subsequently was the University’s Vice President and Provost from 2004 until 2008. He was a founding scientist at the Institute for Clinical Evaluative Sciences (ICES), where he continues as an Adjunct Senior Scientist. He served as founding President and CEO of Public Health Ontario from 2008 until 2014, where he was highly successful in building an academic public health services agency that provided scientific and technical advice to front-line practitioners. Prior to rejoining U of T he served as Chief Academic Strategist with Coursera, a global platform that connects universities and learners with online courses.

He has extensive experience in governance and in his University role serves on the boards of MaRS Innovation, the Vector Institute, the Centre for Commercialization of Regenerative Medicine, the Centre for Commercialization of Antibodies and Biologics, Compute Ontario, TRIUMF, and is co-chair of the Southern Ontario Smart Computing Innovation Platform (SOSCIP). He is also the Vice-Chair of the Board of the Canadian Institute for Health Information. He is also the Vice-Chair of the Board of the Canadian Institute for Health Information and a member of the Board of the Ontario Institute for Cancer Research.

Return to the Board of Directors

Gail Naughton

CSO and Chief Business Development Officer
Histogen Inc., USA

Gail K. Naughton, Ph.D., has spent over 30 years extensively researching the tissue engineering process, holds over 105 U.S. and foreign patents, and has founded two regenerative medicine companies. She served as the Dean of the College of Business at San Diego State University from 2002-2011. Her current venture, Histogen, is focused on the development of novel solutions based on the products of cells grown under simulated embryonic conditions. She currently serves as the Company’s CSO and CBDO and is the inventor of its core technology.

Dr. Naughton has brought several tissue engineered products to market including a product for severe burns (TransCyte), a dermal replacement for diabetic ulcers (Dermagraft), an aesthetic dermal filler (Cosmederm/Cosmeplast) and SkinMedica’s TNS product for skin care. Dr. Naughton has been extensively published and a frequent speaker in the field of tissue engineering and regenerative medicine. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering.

Return to Board of Directors

 

Susan L. Solomon

Susan L. Solomon

Susan L. Solomon is Chief Executive Officer and Co-Founder of The New York Stem Cell Foundation (NYSCF).

Ms. Solomon serves on the Executive Committee of the Alliance for Regenerative Medicine, is a founder and current Chair of NYAMR (New Yorkers for the Advancement of Medical Research) and is a Trustee of the Regional Plan Association.

In 2008, she received a New York State Women of Excellence Award from the Governor, and the Triumph Award from the Brooke Ellison Foundation for her work in establishing NYSCF. In December 2012, she received the Stem Cell Action Leadership Award from the Genetics Policy Institute.

Prior to founding NYSCF, Ms. Solomon was an attorney at Debevoise & Plimpton, served as founding Chief Executive Officer of Sothebys.com, Founder and President of Sony Worldwide Networks, and held executive positions at MacAndrews and Forbes Holdings and MMG Patricof and Co.

Return to Board of Directors

 

David Smith

David Smith

 

Chief Commercial Officer
Healios K.K., Japan

Mr. Smith joined Cambrex Bioproducts in January 2002 as the Business Unit Director of the emerging Cell Therapy business. In 2004, he was promoted to Vice President, Business Development, and in December 2005 to Vice President, Cellular Therapeutics. In this role, he assumed responsibility for contract manufacturing, process development, contract sales, and the introduction of PermaDermTM. Following Lonza’s acquisition of Cambrex Bioproducts in 2007, Mr. Smith became Head of Therapeutic Cell Solutions in 2009 with additional responsibilities for biotherapeutic media, process development, viral vaccines and gene therapies. David now runs the Therapeutic Cell Solutions business unit worldwide. Since his arrival, the cell therapy business has seen significant growth each year.

Prior to joining Lonza, Mr. Smith was Vice President, Corporate Development at Claragen, Inc. and Business Unit Director at Invitrogen. Mr. Smith spent 14 years at The Upjohn Company in various sales and marketing roles, including leading the launch of the Parkinson’s therapeutic, Mirapex. He holds a BS in Pharmacy from Duquesne University in Pittsburgh, PA and a MBA from Wheeling Jesuit University in Wheeling, WV.

Return to Board of Directors

 

Melissa Carpenter

Melissa Carpenter

President, Carpenter Group, Stem Cell Strategies, USA.

Dr. Carpenter received a Ph.D. in the Laboratory of Cellular and Molecular Neurobiology at the University of California, Irvine. For the last 15 years, she has worked on the development of cell therapies using human adult and embryonic stem cells, in academia and industry, in the United States and Canada. This work involved discovery research and the translation of this research into therapies for regenerative medicine, including developing strategies for preclinical development and navigating the regulatory issues surrounding stem cell therapies. This diversity provides a unique perspective concerning the successful development of cell therapies.

At CytoTherapeutics (now StemCells, Inc), Dr. Carpenter derived human neural stem cells and successfully developed the media formulation used for scale-up of these cells. Dr. Carpenter has been involved with human embryonic stem cell (hESC) research since the field was established. She was Director of Stem Cell Biology at Geron Corporation where she was responsible for managing discovery research and preclinical programs aimed at developing therapies for Parkinson’s Disease, Spinal Cord Injury, Cardiac Disease, Liver Disease and Diabetes.

After leaving Geron, Dr. Carpenter held the position of Principal Investigator and Scientist at the Robarts Research Institute and Associate Professor, Faculty of Medicine at the University of Western Ontario. Her Canadian laboratory focused on the epigenetic status of undifferentiated human embryonic stem cells and the signaling mechanisms involved in self-renewal.

As Vice President of Research and Development at Novocell Inc, Dr. Carpenter was responsible for the translation of the research program to preclinical development and developing the regulatory strategy for the delivery of an encapsulated human embryonic stem cell derived product into Diabetes patients.

Dr. Carpenter is credited with more than 20 issued patents and over 45 publications in stem cell biology and related fields.

Return to Board of Directors

 

Duncan Stewart

Duncan Stewart

Chief Executive Officer and Scientific Director
Ottawa Hospital Research Institute

Dr. Duncan Stewart is a pioneering Canadian cardiovascular researcher, who is recognized for his many important discoveries in blood vessel biology as well as his dedication to translating these discoveries into benefits for patients and society. After beginning his career in academic cardiology at McGill University in Montreal, he moved to Toronto in 1994 as Head of Cardiology at St. Michael’s Hospital and later Director of the Division of Cardiology at the University of Toronto. In 2004 he assumed the role of the executive Director of the McLaughlin Centre for Molecular Medicine at the University of Toronto and in 2007 he was recruited as the CEO and Scientific Director of the Ottawa Hospital Research Institute (OHRI) in 2007.

Dr. Stewart has made a number of seminal discoveries elucidating the importance of endothelial factors in health and disease, notably the role of the nitric oxide system in angiogenesis and the role of endothelin-1 in pulmonary hypertension. He is also a leader in developing cell and gene based therapies for cardiovascular disease. He led the first Canadian clinical trials testing angiogenic gene therapy using VEGF to stimulate blood vessels growth and heart repair after heart attacks. He is also spearheading the world’s first clinical trial of a gene-enhanced cell therapy for pulmonary hypertension, using endothelial progenitor cells engineered to over-express endothelial nitric oxide synthase. He is also poised to launch the first gene-enhanced progenitor cell therapy trial for post heart-attack repair, and he is leading a Canadian effort to initiate the world’s first trial of mesenchymal stem cells for the treatment of acute lung injury and acute respiratory distress syndrome.

Dr. Stewart has published more than 200 peer-reviewed manuscripts and has received a number of distinctions and prizes, including the Dexter Man Chair of Cardiology and Research Achievement Award of the University of Toronto, and the Research Achievement Award of the Canadian Cardiovascular Society. Throughout his career, Dr. Stewart has demonstrated leadership in bringing diverse groups of clinicians and scientists together to put Canada on the world stage for translational cardiovascular and regenerative medicine research.

Return to Board of Directors

Lita Nelsen

Lita Nelsen

Director of Technology Licensing Office
Massachusetts Institute of Technology, USA

Ms. Nelsen earned B.S. and M.S. degrees in Chemical Engineering from M.I.T. and an M.S. in Management from M.I.T. as a Sloan Fellow.

Lita Nelsen is the Director of the Technology Licensing Office at the Massachusetts Institute of Technology, where she has been since 1986.  This office manages over 500 new inventions per year from M.I.T., the Whitehead Institute, and Lincoln Laboratory.  Typically, they negotiate over 100 licenses, and start up over 20 new companies per year

Prior to joining the M.I.T. Technology Licensing Office, Ms. Nelsen spent 20 years in industry, primarily in the fields of membrane separations, medical devices, and biotechnology, at such companies as Amicon, Millipore, Arthur D. Little, Inc., and Applied Biotechnology.

Ms. Nelsen was the 1992 President of the Association of University Technology Managers and serves on the board of Mount Auburn Hospital, and the Scientific Advisory Board of the Children’s Hospital Oakland Research Foundation.  She serves as the intellectual property advisor to the International AIDS Vaccine Initiative and is a founding and current board member of the Center for Management of Intellectual Property in Health Research.

Ms. Nelsen is widely published in the field of technology transfer and university/industry collaborations and was a CMI Fellow at the University of Cambridge with the Cambridge MIT Institute studying university/industry/government partnerships in technology transfer and local economic development. She is a co-founder of Praxis, the UK University Technology Transfer Training Programme.

Return to Board of Directors

 

Font Resize
Enable Contrast